• 02-JUN-2015

  • SOURCE: Sirtex Medical Ltd

SIRFLOX Study Presented at ASCO 2015 Annual Meeting

Clinical investigators cite significance of 7.9 month improvement in Progression-Free Survival in the liver for patients with unresectable metastatic colorectal cancer (mCRC) treated first line with SIR-Spheres® Y-90 resin microspheres plus chemotherapy